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BACKGROUND Filamin C (encoded by the FLNC gene) is essential for sarcomere attachment 
to the plasmatic membrane. FLNC mutations have been associated with myofibrillar myopathies 
and cardiac involvement has been reported in some carriers. Accordingly, since 2012 we have 
included FLNC in the genetic screening of patients with inherited cardiomyopathies and sudden 
death. 
OBJECTIVES We aimed to demonstrate the association between truncating mutations in FLNC 
and the development of high-risk dilated and arrhythmogenic cardiomyopathies. 
METHODS FLNC was studied by next-generation sequencing in 2,877 patients with inherited 
cardiovascular diseases. We identified a characteristic phenotype in probands with truncating 
mutations in FLNC. Clinical and genetic evaluation of 28 affected families was performed. 
Localization of filamin C in cardiac tissue was analyzed in patients with truncating FLNC 
mutations using immunohistochemistry. 
RESULTS We identified 23 truncating mutations in 28 probands previously diagnosed with 
dilated, arrhythmogenic, or restrictive cardiomyopathies. Truncating FLNC mutations were 
absent in patients with other phenotypes, including 1,078 individuals with hypertrophic 
cardiomyopathy. Fifty-four mutation carriers were identified among 121 screened relatives. The 
phenotype consisted of left ventricular dilation (68%), systolic dysfunction (46%), and 
myocardial fibrosis (67%); inferolateral negative T waves with low voltages on 
electrocardiogram (33%); ventricular arrhythmias (82%); and frequent sudden cardiac death (40 
cases in 21 of 28 families). Clinical skeletal myopathy was not observed. Penetrance was >97% 
in carriers older than 40 years. Truncating mutations in FLNC cosegregated with this phenotype 
with a dominant inheritance pattern (combined logarithm of the odds score: 9.5). 
Immunohistochemical stainings of myocardial tissue showed no abnormal filamin C aggregates 
in patients with truncating FLNC mutations. 
CONCLUSIONS Truncating mutations in FLNC caused an overlapping phenotype of dilated 
and left dominant arrhythmogenic cardiomyopathies complicated by frequent premature sudden 
death. Prompt implantation of a cardiac defibrillator should be considered in affected individuals 
harboring truncating mutations in FLNC. 
 




CMR = cardiac magnetic resonance 
DCM = dilated cardiomyopathy 
ECG = electrocardiogram 
FLNC = Filamin C gene 
HCM = hypertrophic cardiomyopathy 
LOD = logarithm of the odds 
LV = left ventricle/ventricular 
RV = right ventricle/ventricular 
VT = ventricular tachycardia  
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Filamins cross-link actin filaments forming a widespread network in cardiac and skeletal 
muscles cells (1). Their principal function is to anchor membrane proteins to the cytoskeleton 
(2,3). Gamma filamin or filamin C is one of 3 filamin-related proteins, and it is encoded by the 
FLNC gene (4). Filamin C also binds to several proteins in the Z-disk of the sarcomere (5-7). 
Mutations in FLNC were initially related to a particular form of skeletal myofibrillar 
myopathy associated in some cases with a nonspecified form of “cardiomyopathy” (8-12). For 
that reason, since 2012, we have included FLNC in the genetic screening of patients with 
inherited cardiomyopathies and sudden death. 
Here we describe a characteristic form of cardiomyopathy caused by truncating mutations 
in FLNC in the absence of clinical skeletal myopathy. The phenotype appears as an overlapping 
of dilated and arrhythmogenic cardiomyopathies, characterized by variable degrees of left 
ventricular (LV) dilation and systolic dysfunction, prominent subepicardial and/or 
intramyocardial fibrosis of the left ventricle, frequent ventricular arrhythmias, and sudden 
cardiac death. 
Methods 
From February 2012 to August 2015, FLNC was evaluated by next-generation 
sequencing in 2,877 patients with different inherited cardiovascular diseases (Online Table 1). 
The phenotypes were those established by each center prior to the genetic study. We identified 
28 unrelated probands with truncating mutations in FLNC. Clinical and genetic familial cascade 
screenings were performed in those cases who agreed. All individuals gave their written consent 
to participate in this study. The project was approved by the different local ethics committees. 
Genetic Studies 
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Coding exons and intronic boundaries of 213 genes (Online Table 2) related to inherited 
cardiovascular diseases and sudden death were captured using a custom probe library (SureSelect 
Target Enrichment Kit for Illumina paired-end multiplexed sequencing method; Agilent 
Technologies, Santa Clara, California). Sequencing was performed using the HiSeq 1500 
platform (Illumina, Inc., San Diego, California) with 2 x 100 base read length following Illumina 
protocols. Bioinformatics analysis was performed by means of a custom pipeline including 
software for variant calling, genotyping, and annotation. Mean coverage for all the evaluated 
genes ranged between 250x and 400x. Read depth of every nucleotide from genes related to the 
referring phenotype was >30x. Those exons that did not fulfil this standard were complementary 
sequenced by the Sanger technique. All exons of FLNC were completely covered (>30x). 
Information regarding frequency in different populations (1,000 Genomes Project, Exome 
Variant Server, Exome Aggregation Consortium) was considered. The allele frequency threshold 
to consider a mutation clinically relevant was ≤0.1%. Pathogenicity of variants was classified 
according to current recommendations (13). 
Those variants considered clinically relevant according to the patient’s phenotype were 
confirmed using Sanger sequencing. There is a pseudogene located 53.6 kilobases downstream 
from the functional FLNC gene, which is 98% homologous to exons 46, 47, and 48. All the 
variants identified in those exons were sequenced using specific primers designed to confirm that 
they corresponded to the real FLNC sequence and not to the pseudogene (14). Cascade genetic 
screening in relatives was performed using Sanger sequencing. 
We defined truncating mutations in FLNC as those that introduce a premature stop codon 
in the protein’s sequence (nonsense or frameshift) or that could alter the splicing process 
according to the predictions of 5 in silico tools: MaxEntScan, Splice-Site Finder (SSF), HSF, 
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NNSPLICE, and GeneSplicer. All the genetic variants included in the present study were 
predicted to disrupt the protein function. 
Statistical Analysis 
The cumulative probability for the occurrence of sudden death, appropriate defibrillator 
shock, heart failure (HF) death, or cardiac transplant was estimated by using the Kaplan-Meier 
method and factors were compared using the log-rank (Mantel-Cox) method. Survival was 
calculated from birth. A 2-sided p value < 0.05 was considered statistically significant. Statistical 
analyses were performed using SPSS Statistics Version 21.0 (IBM Corporation, Armonk, New 
York). 
Two-point logarithm of the odds (LOD) score was calculated in 23 families using the 
Superlink-Online SNP tool with the following settings: disease mutant gene frequency = 0.001; 
dominant mode of inheritance, penetrance = 99%; and θ = 0. 
Immunohistochemistry 
In order to analyze the presence of filamin C aggregates as a potential cause of 
myocardial injury, we compared 3 patients with truncating mutations in FLNC (26958-II:1, 
36203-III:3, and 25767-III:1) with 3 control samples. Myocardial samples from patients were 
obtained from necropsy or explanted hearts. Immunohistochemistry analysis was performed 
using a specific antibody against the N-terminal extreme of filamin C. In brief, 5 micron-thick 
sections were obtained from paraffin-embedded tissue blocks from patients with truncating 
FLNC mutations and controls. After rehydration, samples were heated for 15 min in the 
microwave oven to induce epitope retrieval in Tris-EDTA Buffer, pH 9.0 and were subsequently 
incubated at room temperature for 15 min to enhance penetration of the antibody. Slides were 
then washed twice in a 0.1% Tween-20 Tris-buffered saline (TBS-T) solution and blocked with 
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Avidin/Biotin Blocking reagent according to the manufacturer's protocol (Vector Laboratories, 
Burlingame, California). After washing with TBS-T and blocking with a 15% goat serum TBS-T 
solution, slides were incubated with rabbit polyclonal anti-filamin C gamma (1:50; 
MBS2026155; MyBiosource, San Diego, California) raised against the N-terminal peptide of the 
protein overnight at 4º C. Slides were TBS-T-washed and incubated with a horseradish 
peroxidase goat anti-rabbit secondary antibody for 30 min at room temperature. Vectastain ABC 
kit was used to amplify the signal, and DAB substrate kit was used for peroxidase detection 
(Vector Laboratories). Counterstaining with hematoxylin was carried out before dehydration and 
mounting the slides with DPX. Pictures were taken with a Nikon 90i microscope at different 
magnifications. 
Results 
Twenty-three different truncating mutations in FLNC were identified in 28 unrelated 
probands (Figure 1; Online Tables 3 and 4). Previous diagnoses were dilated cardiomyopathy 
(DCM) in 20 patients, arrhythmogenic cardiomyopathy in 7 (all of them with predominant LV 
involvement), and restrictive cardiomyopathy in 1. No pathogenic mutations in other genes were 
identified in any of them. We did not find truncating mutations in FLNC among 2,105 
individuals with other inherited cardiovascular diseases, including 1,078 patients with 
hypertrophic cardiomyopathy (HCM) (Online Table 1). The prevalence of truncating FLNC 
mutations in this heterogeneous global cohort was low (28 out of 2,877 patients screened = 
0.97%). However, if we referred to the specific phenotypes where this type of mutation was 
found, the proportion was significantly higher: 20 of 508 patients with DCM (3.9%), 7 of 219 




In total, 149 individuals (28 probands and 121 relatives) were clinically and genetically 
evaluated. Fifty-four relatives (45%) carried the FLNC mutation identified in the proband. 
Cardiac alterations were evidenced in 74% of relatives with the mutation (n = 40). Mean age at 
presentation in affected carriers was 41 ± 15 years (range: 0.3 to 71). Eleven (92%) of 12 healthy 
mutation carriers were <40 years at last follow-up (mean 32 ± 16 years; range: 6 to 72). None of 
the 67 noncarriers were clinically affected. Complete cosegregation of truncating mutations in 
FLNC with a particular cardiac phenotype was observed in 23 families who agreed to be 
investigated (combined LOD score: 9.5) (Online Table 5, Online Figure 1). 
In terms of clinical characteristics of carriers of truncating mutations in FLNC (Table 1), 
exertional dyspnea and palpitations were the most frequent presentation symptoms. Three 
probands were asymptomatic at the moment of diagnosis and were studied due to family history 
of sudden death. Of the affected relatives with positive genotype, 43% were asymptomatic and 
diagnosed through family screening. 
Most of the probands showed LV dilation (end-diastolic diameter: 61 ± 13 mm) and 
systolic dysfunction (ejection fraction (EF): 34 ± 13%), which were also frequent among 
relatives (end-diastolic diameter: 53 ±9 mm; EF: 52 ± 12%). Structural abnormalities in the right 
ventricle (dilation, akinesia, dyskinesia, or systolic dysfunction) were observed in 10 probands 
(36%). All of them presented LV involvement as well. Five (14%) of the 36 affected relatives 
with available information showed mild right ventricular (RV) abnormalities. Mild hypertrophy 
(maximal wall thickness ≤14 mm) not fulfilling diagnostic criteria for HCM was described in 10 
carriers (13%). 
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Most patients were in sinus rhythm and cardiac conduction defects were mild and 
uncommon. Negative T waves were frequently seen in left precordial (12%), inferior (6%), left 
and inferior (9%), or left and right precordial leads (4%), while no patient presented isolated 
negative T waves in right precordial leads. Low QRS voltages in the limb leads were found in 
25% of mutation carriers (Online Figure 2). Terminal QRS duration >55 ms in leads V1 to V3 
was recorded in 18% of carriers evaluated. No individuals showed epsilon waves. A signal 
average electrocardiogram (ECG) was positive in 4 of 6 individuals tested. 
Ventricular arrhythmias were extremely frequent among carriers (82%). Frequent 
ventricular extrasystoles (>500/24 h) and nonsustained ventricular tachycardia (VT) were the 
most common. Sustained VT was recorded in 10 of 55 carriers with available information, in 3 
of them during exercise. 
Electrophysiological study was performed in 8 patients and ventricular arrhythmias were 
induced in 4 (2 nonsustained VTs, 1 VT, and 1 ventricular fibrillation). 
The presence of myocardial fibrosis was assessed by cardiac magnetic resonance (CMR) 
in 15 probands; 11 of them presented areas with late-gadolinium enhancement exclusively 
affecting the LV wall. Two of these subjects died suddenly (ages 22 and 25 years, respectively), 
and fibrosis was confirmed on cardiac histology (Figures 2A and 2B). Three of 13 probands 
without a CMR study showed myocardial fibrosis confined to the left ventricle on 
necropsy/explanted heart (1 died suddenly at age 17 years, and the other 2 were transplanted at 
ages 1 and 60 years, respectively) (Figures 2C and 2D). Endomyocardial biopsy of the RV 
revealed large amounts of fibrosis in the proband diagnosed with restrictive cardiomyopathy. 
Globally, 75% of those investigated probands developed cardiac fibrosis predominantly affecting 
the LV wall. Among relatives with the mutation, 16 of 31 evaluated relatives (52%) showed 
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significant amounts of myocardial fibrosis mainly affecting the LV on CMR (n = 13) or in the 
necropsy (n = 2); 1 relative showed fibrosis on endomyocardial biopsy of the RV. Left 
ventricular myocardial fibrosis was mainly subepicardial. A concentric pattern and extension to 
intramyocardial or transmural involvement was observed in some cases. Two patients who were 
transplanted due to advanced HF showed endomyocardial fibrosis. 
At initial evaluation, no patient suffered from muscle weakness nor showed signs of 
skeletal myopathy. Mild elevation of plasmatic creatine kinase levels (<2-fold of upper normal 
value) was found in only 3 of 40 evaluated carriers. Only 1 of them (proband from family 31277) 
presented muscle weakness in the lower limbs during follow-up. This patient had been diagnosed 
with restrictive cardiomyopathy at 29 years and had received a cardiac transplant at age 45. An 
electromyography study at 59 years revealed moderate myopathic changes. However, this 
woman was under therapy with simvastatin and corticosteroids that could explain these findings. 
Palmoplantar keratoderma was observed and cosegregated with the cardiac phenotype 
and the FLNC mutation (c.4127+1delG) in 4 members from family 29876 (Online Figures 1 and 
Online Figure 3). This finding was not observed in other families from this series. 
Events 
Twelve carriers suffered cardiac arrest (mean age at event 42 ± 16 years; range: 17 to 68), 
being the first manifestation of the disease in 4 of them. All subjects with available data 
presented LV systolic dysfunction (n = 9; mean LVEF: 39.6 ± 12%; range: 21 to 4) and 
myocardial fibrosis confined to the left ventricle (n = 7). Ventricular arrhythmias had been 
investigated prior to the event in 6 of these 12 individuals and all of them showed frequent 
ventricular extrasystoles and/or nonsustained VT. 
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Twenty-six affected mutation carriers received or were recommended to have a cardiac 
defibrillator implanted. The indication was primary prevention in 17 (1 declined the indication 
and 1 died suddenly waiting for the implant) and secondary prevention in 9, after suffering a 
symptomatic sustained VT (n = 7) or after an aborted cardiac arrest (n = 2); all of them exhibited 
LV systolic dysfunction. Appropriate shocks were recorded in 3 of 15 (20%) primary prevention 
patients and in 5 of 9 (56%) secondary prevention cases (mean time to shock: 53 ± 39 months; 
range: 0.1 to 96) (Online Figure 4). 
Five carriers underwent heart transplantation due to markedly reduced EF (n = 4) or 
restrictive filling with severe pulmonary hypertension (n = 1). Mean age at transplantation was 
43 ± 24 years (range: 1 to 60). 
Considering both carriers (n = 12) and affected relatives without genetic study (n = 28), 
there have been 40 sudden deaths in 21 of the 28 evaluated families. Mean age at event was 44 ± 
17 years (range: 15 to 80); 65% occurred in individuals ≤50 years old. Figure 3 shows the 
survival curve for sudden death/appropriate defibrillator shock/HF death/heart transplant in 
clinically or genetically affected individuals. 
Immunohistochemistry 
Immunohistochemical stainings of myocardial tissue from patients carrying truncating 
mutations in FLNC showed no abnormal filamin C aggregates in the cytoplasm. In contrast, we 
observed that antibodies against filamin C stained the intercalated disk region in both patients 
and controls (Figure 4). 
Discussion 
We describe the association of truncating mutations in FLNC with a particular 
overlapping phenotype of dilated and left dominant arrhythmogenic cardiomyopathies 
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complicated by frequent premature sudden death. Cosegregation of truncating FLNC mutations 
with this phenotype with a dominant mode of transmission was clearly demonstrated in this 
international series of 28 families. Mutation penetrance was >97% in carriers older than 40 years. 
Carriers developed ventricular dilation with reduced EF, especially affecting the left 
ventricle. The majority of the affected carriers had been diagnosed with DCM. However, a 
significant number of patients had been diagnosed with left-dominant arrhythmogenic 
cardiomyopathy. Diagnosis of arrhythmogenic cardiomyopathy is challenging and based on 
multicategorical criteria (15). Left-dominant arrhythmogenic cardiomyopathy mimics idiopathic 
dilated cardiomyopathy and its clinical diagnostic criteria have not been formally established. 
Many authors have suggested that ventricular arrhythmias coming from a fibrotic LV wall in the 
absence of RV involvement could be an expression of left-dominant arrhythmogenic 
cardiomyopathy (16-18). This phenotype frequently presents with inferolateral negative T waves, 
mild-to-moderate LV systolic dysfunction, and regional dyskinesia, all of which were identified 
in several of our patients. 
These patients with truncating mutations in FLNC share clinical characteristics both of 
desmosomal mutations and of laminopathies and desminopathies. Ventricular arrhythmias, likely 
related to the presence of LV myocardial fibrosis, and a high incidence of sudden death may 
appear in all of them (19,20). Nevertheless, isolated or predominant RV involvement, common 
in desmosomal mutations, was not observed in our patients. On the other hand, cardiac 
conduction abnormalities were mild and infrequent, while they are common and severe in 
patients with pathogenic lamin A/C, emerin, or desmin mutations (19-21). These differences 
likely reflect the involvement of different pathogenic mechanisms. 
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All mutations identified in our work were novel except for c.3791-1G>C and 
c.7251+1G>A, although both variants have been reported in patients with DCM (22-24). The 
phenotype of these cases resembles our findings: high prevalence of ventricular arrhythmias and 
sudden cardiac death (even in the absence of severe LV dilation and dysfunction) with no 
skeletal muscle involvement. 
Filamin C protein is widely expressed in cardiac myocytes and participates in mechanical, 
sensory, and signal transduction between sarcomeres and plasmatic membranes (2-4). Its 
participation in the attachment of the sarcomere´s Z-disk to the sarcolemma (costameres) and to 
the intercalated disks allows for cell-to-cell mechanical force transduction (7). Filamin C directly 
interacts with 2 protein complexes that link the subsarcolemmal actin cytoskeleton to the 
extracellular matrix: the dystrophin-associated glycoprotein and the integrin complexes (6). At 
intercalated disks, filamin C is located in the fascia adherens where myofiber ends reach the 
sarcolemma, adjacent to the position of desmosomal junctions (Figure 5) (25). 
Several mutations in FLNC have been previously associated with a particular form of 
myofibrillar myopathy (8-12). This phenotype is mainly characterized by late-onset (usually 
starting in the fourth decade of life) skeletal myopathy, which usually initially involves proximal 
and later distal limb muscles. Cardiac involvement has been described in some patients, with 
approximately 30% of carriers showing a nonspecific and poorly characterized cardiomyopathy 
(9). History of early sudden death has been described in these families, but previous publications 
did not provide details about these findings (8-12). Mutations in FLNC previously identified in 
myofibrillar myopathy are mostly missense and in-frame indels. Only 2 truncating mutations 
were reported in those patients: a nonsense variant close to the C-terminal end of the protein and 
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a frameshift variant producing a stop codon in exon 30 (8,12). Abnormal cytoplasmic filamin C 
aggregates were demonstrated to play a pathogenic role in most of these cases. 
Immunohistochemical analysis showed normal filamin C staining in intercalated disks. 
The absence of abnormal filamin C aggregates in the cytoplasm of cardiomyocytes of our 
patients with truncating FLNC mutations suggests that the mechanism involved in this type of 
mutations is different from that previously associated with myofibrillar myopathy. One potential 
explanation is that truncating mutations in FLNC would decrease the level of normal filamin C 
by means of haploinsufficiency. This alteration could affect mechanical force transduction at 
intercalated disks and costameres by weakening the binding of the Z-disk to the plasmatic 
membrane. Tissues exposed to high mechanical force generation, such as the LV myocardium, 
could be particularly affected. Myocardial fibrosis, together with dilation and systolic 
dysfunction of the left ventricle, could be the consequences of this functional alteration. In fact, 
Begay et al. recently demonstrated in a zebrafish knockdown model that 2 splicing variants in 
FLNC produced a reduction in cardiac filamin C protein levels with Z-disk and sarcomere 
disorganization (24). These findings additionally supported haploinsufficiency as the underlying 
functional mechanism of truncating mutations in FLNC. In a previous study, a medaka fish 
harboring a homozygous nonsense mutation in FLNC showed early rupture of the myocardial 
ventricular wall and progressive skeletal muscle degeneration in late embryonic stages. The 
mutant embryo fish showed fewer sarcomere bundles attached to the intercalated disks and 
detachment of myofibrils from sarcolemma and intercalated disks, with focal Z-disk destruction 
(26). 
Clinical signs of skeletal myopathy were specifically and systematically investigated 
among carriers. It is noteworthy that only 1 of the carriers in our series showed clinical signs of 
15 
skeletal myopathy. Although skeletal biopsies were not performed, creatine kinase levels were 
within the normal limits in almost all carriers who were investigated. Previous studies suggested 
that skeletal myopathy would be the main phenotype associated with pathogenic FLNC 
mutations. Our data showed that cardiac disease would be the main consequence of truncating 
mutations in this gene. Since most previous publications focused on skeletal myopathy and 
cardiac examinations were not routinely performed, subtle cardiac abnormalities only detectable 
through Holter ECG and CMR could have been missed.  
It has been suggested that mutations in FLNC could explain nearly 10% of cases of HCM 
in patients without mutations in the main sarcomeric genes (27). Seven of 8 novel mutations 
identified in this work were missense variants. In line with our results, none of the carriers 
showed symptoms of skeletal myopathy. Moreover, muscle biopsies performed in 2 patients 
showed normal histology and histochemistry. It is noteworthy that in this report, patients with 
FLNC mutations showed lower LV wall thickness than patients without mutations in FLNC. In 
fact, 65% of carriers who developed hypertrophy showed a maximal wall thickness ≤15 mm. 
Whether missense mutations lead to HCM and truncating mutations to dilated/left dominant 
arrhythmogenic cardiomyopathies would need to be confirmed in future studies, but so far we 
have not identified any truncating FLNC mutation in more than 1,000 patients with HCM. Our 
data clearly suggest that truncating FLNC mutations are not related to the development of HCM. 
Two novel missense mutations in FLNC have recently showed cosegregation with 
restrictive cardiomyopathy in 2 Caucasian families (28). We postulate that the molecular 
mechanism associated with these missense mutations could be different to truncating mutations. 
However, some clinical characteristics of these 2 families resembled our findings. Several 
carriers showed different amounts of myocardial fibrosis on cardiac histology. Moreover, some 
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cases presented T wave abnormalities on ECG or LV systolic dysfunction on echocardiogram. 
Unfortunately, the assessment of ventricular arrhythmias on Holter ECG and the evaluation of 
areas with late-gadolinium enhancement with CMR were not reported. 
Study Limitations 
Patients were genetically screened for genes previously associated with inherited cardiac 
conditions. The presence of additional mutations in other genes contributing to the phenotype 
cannot be ruled out. Cosegregation studies were limited in some families due to the low number 
of relatives available for screening. Clinical assessment was incomplete in some carriers. The 
presence of skeletal myopathy among carriers was not assessed using more specific diagnostic 
tools such as magnetic resonance imaging or skeletal muscle biopsies.  
The available data used for survival curves could be insufficient to accurately estimate 
the prognosis associated with truncating mutations in FLNC. Additional studies are needed to 
specifically determine the functional mechanisms behind the development of cardiomyopathy 
among carriers of truncating mutations in FLNC. 
Conclusions 
Truncating mutations in FLNC are associated with a characteristic cardiac phenotype that 
includes LV dilation with systolic dysfunction and myocardial fibrosis. Ventricular arrhythmias 
are extremely frequent, and families with these mutations show a high incidence of sudden 
cardiac death. We did not find evidence of skeletal myopathy in our series, suggesting a new and 
exclusive cardiac phenotype associated with this type of mutations. 
FLNC should be systematically included in the genetic studies of patients diagnosed with 
dilated, arrhythmogenic, or restrictive cardiomyopathies. The identification of pathogenic 
truncating mutations should prompt a thorough clinical evaluation that includes CMR imaging 
17 
and Holter ECG monitoring. Implantable defibrillators should probably be considered even in 
cases with only moderate systolic dysfunction in the presence of myocardial fibrosis and 
ventricular arrhythmias.  
18 
Perspectives 
COMPETENCY IN MEDICAL KNOWLEDGE: Truncating mutations in FLNC, previously 
related to skeletal myopathy, can also be associated cardiomyopathy in the absence of clinical 
skeletal manifestations. These mutations cause an overlapping phenotype of dilated and 
arrhythmogenic cardiomyopathies, and should be suspected when a cardiomyopathy is 
characterized by LV systolic dysfunction and/or dilation, fibrosis, ventricular arrhythmias, and a 
family history of sudden death. 
COMPETENCY IN PATIENT CARE: Patients with suspected FLNC mutations can be 
evaluated by genetic testing, CMR (to exclude myocardial fibrosis), cardiac arrhythmia 
monitoring, and stress testing (to evaluate ventricular arrhythmias). 
TRANSLATIONAL OUTLOOK: Further studies are needed to clarify the mechanisms linking 
truncating FLNC mutations to the clinical manifestations of these cardiomyopathies and to 
determine whether implantation of a cardiac defibrillator improves survival in carriers with 





1. Stossel TP, Hartwig JH. Interactions between actin, myosin, and an actin binding protein 
from rabbit alveolar macrophages. Alveolar macrophage myosin Mg-2+-adenosine 
triphosphatase requires a cofactor for activation by actin. J Biol Chem 1975;250:5706-12. 
2. Stossel TP, Condeelis J, Cooley L, et al. Filamins as integrators of cell mechanics and 
signalling. Nat Rev Mol Cell Biol 2001;2:138-45. 
3. van der Flier A, Sonnenberg  A. Structural and functional aspects of filamins. Biochim 
Biophys Acta 2001;1538:99-117. 
4. Maestrini E, Patrosso C, Mancini M, et al. Mapping of two genes encoding isoforms of 
the actin binding protein ABP-280, a dystrophin like protein, to Xq28 and to chromosome 7. 
Hum Mol Genet 1993;2:761-6. 
5. Ohashi K, Oshima K, Tachikawa M, et al. Chicken gizzard filamin, retina filamin and 
cgABP260 are respectively, smooth muscle-, non-muscle- and pan-muscle-type isoforms: 
distribution and localization in muscles. Cell Motil Cytoskeleton 2005;61:214-25. 
6. Gontier Y. The Z-disc proteins myotilin and FATZ-1 interact with each other and are 
connected to the sarcolemma via muscle-specific filamins. J Cell Sci 2005;118:3739-49. 
7. Van Der Ven PFM, Wiesner S, Salmikangas P, et al. Indications for a novel muscular 
dystrophy pathway: γ-Filamin, the muscle-specific filamin isoform, interacts with myotilin. J 
Cell Biol 2000;151:235-47. 
8. Vorgerd M, van der Ven PFM, Bruchertseifer V, et al. A mutation in the dimerization 
domain of filamin c causes a novel type of autosomal dominant myofibrillar myopathy. Am J 
Hum Genet 2005;77:297-304. 
20 
9. Kley RA, Hellenbroich Y, Van Der Ven PFM, et al. Clinical and morphological 
phenotype of the filamin myopathy: A study of 31 German patients. Brain 2007;130:3250-64. 
10. Luan X, Hong D, Zhang W, Wang Z, Yuan Y. A novel heterozygous deletion-insertion 
mutation (2695-2712 del/GTTTGT ins) in exon 18 of the filamin C gene causes filaminopathy in 
a large Chinese family. Neuromuscul Disord 2010;20:390-6. 
11. Duff RM, Tay V, Hackman P, et al. Mutations in the N-terminal actin-binding domain of 
filamin C cause a distal myopathy. Am J Hum Genet 2011;88:729-40. 
12. Guergueltcheva V, Peeters K, Baets J, et al. Distal myopathy with upper limb 
predominance caused by filamin C haploinsufficiency. Neurology 2011;77:2105-14.  
13. Richards S, Aziz N, Bale S, et al. Standards and guidelines for the interpretation of 
sequence variants: a joint consensus recommendation of the American College of Medical 
Genetics and Genomics and the Association for Molecular Pathology. Genet Med 2015;17:405-
24. 
14. Odgerel Z, Van Der Ven PFM, Fürst DO, Goldfarb LG. DNA sequencing errors in 
molecular diagnostics of filamin myopathy. Clin Chem Lab Med 2010;48:1409-14. 
15. Marcus FI, McKenna WJ, Sherrill D, et al. Diagnosis of arrhythmogenic right ventricular 
cardiomyopathy/dysplasia: Proposed Modification of the Task Force Criteria. Eur Heart J 
2010;31:806-14. 
16. Sen-Chowdhry S, Syrris P, Prasad SK, et al. Left-Dominant Arrhythmogenic 
Cardiomyopathy. J Am Coll Cardiol 2008;52:2175-87. 
17. Berte B, Denis A, Amraoui S, et al. Characterization of the Left-Sided Substrate in 
Arrhythmogenic Right Ventricular Cardiomyopathy. Circ Arrhythm Electrophysiol 2015;8:1403-
12. 
21 
18. Lopez-Ayala JM, Gomez-Milanes I, Sanchez Munoz JJ, et al. Desmoplakin truncations 
and arrhythmogenic left ventricular cardiomyopathy: characterizing a phenotype. Europace 
2014;16:1838-46. 
19. van Berlo JH, de Voogt WG, van der Kooi AJ, et al. Meta-analysis of clinical 
characteristics of 299 carriers of LMNA gene mutations: do lamin A/C mutations portend a high 
risk of sudden death? J Mol Med (Berl) 2005;83:79-83. 
20. Dalakas MC, Park KY, Semino-Mora C, Lee HS, Sivakumar K, Goldfarb LG. Desmin 
myopathy, a skeletal myopathy with cardiomyopathy caused by mutations in the desmin gene. N 
Engl J Med 2000;342:770-80. 
21. Holaska JM. Emerin and the nuclear lamina in muscle and cardiac disease. Circ Res 
2008;103:16-23. 
22. Golbus JR, Puckelwartz MJ, Dellefave-Castillo L, et al. Targeted analysis of whole 
genome sequence data to diagnose genetic cardiomyopathy. Circ Cardiovasc Genet 2014;7:751-9.  
23. Deo RC, Musso G, Tasan M, et al. Prioritizing causal disease genes using unbiased 
genomic features. Genome Biol 2014;15:3274. 
24. Begay RL, Tharp CA, Martin A, et al. FLNC Gene Splice Mutations Cause Dilated 
Cardiomyopathy. JACC Basic Transl Sci 2016. DOI: 10.1016/j.jacbts.2016.05.004. 
25. van der Ven PFM, Ehler E, Vakeel P, et al. Unusual splicing events result in distinct Xin 
isoforms that associate differentially with filamin c and Mena/VASP. Exp Cell Res 
2006;312:2154-67. 
26. Fujita M, Mitsuhashi H, Isogai S, et al. Filamin C plays an essential role in the 
maintenance of the structural integrity of cardiac and skeletal muscles, revealed by the medaka 
mutant zacro. Dev Biol 2012;361:79-89. 
22 
27. Valdés-Mas R, Gómez J, Coto E, et al. Mutations in filamin C cause a new form of 
familial hypertrophic cardiomyopathy. Nat Commun 2014;5:5326.  
28. Brodehl A, Ferrier RA, Hamilton SJ, et al. Mutations in FLNC are Associated with 
Familial Restrictive Cardiomyopathy. Hum Mutat 2015;37:269-79.  
23 
Figure Legends 
Central Illustration: Truncating FLNC Mutations and Dilated and Arrhythmogenic 
Cardiomyopathies. Truncating FLNC mutations could alter intercalated disks and costameres, 
weakening the attachment of myocytes. The consequence is a particular form of cardiomyopathy 
mainly characterized by left ventricular dilation and systolic dysfunction, myocardial fibrosis 
predominantly affecting the left ventricle, and a high burden of ventricular arrhythmias that leads 
to sudden cardiac death. 
 
Figure 1: Spatial Distribution of Truncating Mutations in Filamin C Protein. Mutations 
affecting coding exonic regions are shown above and mutations affecting intronic canonical 
splicing sites are shown below the diagram of boxes with numbers representing the 24 
immunoglobulin-like repeats of filamin C. CH1 = calponin homology domain 1; CH2 = calponin 
homology domain 2; (#) = mutations identified in 2 unrelated families. 
 
Figure 2: LV Myocardial Fibrosis observed in two carriers of truncating FLNC mutations. 
Left ventricular (LV) fibrosis is seen in 2 carriers of truncating FLNC mutations. The proband of 
family 32406, who died suddenly playing soccer at age 22, was found to have (A) 
circumferential subepicardial fibrosis (arrows) on necropsy on the same localization (B) as late-
gadolinium enhancement (arrows) detected on cardiac magnetic resonance performed prior to 
death Also seen are (C) circumferential LV intramyocardial fibrosis (arrows) on necropsy and 
(D) myocardial fibrosis (light blue) affecting the anterior wall of the left ventricle (Masson’s 
trichrome, 2x) of the proband of family 26958, who died suddenly at age 17 after a soccer mat.  
 
24 
Figure 3: Major Cardiovascular Events. In families with truncating FLNC mutations, freedom 
from sudden death/appropriate defibrillator shock/heart failure death/heart transplant in all 
clinically or genetically affected individuals (A) and discriminated by sex (B) decreased as 
individuals aged. 
 
Figure 4: Filamin C Localization in Cardiac Tissue. Immunohistochemical staining shows the 
presence of filamin C only in intercalated disks of 3 controls (A to C) and 3 patients with 
truncating FLNC mutations (D to F). Hematoxylin counterstain was used to detect cell nuclei. 
Scale bar = 100 μm. 
 
Figure 5: Cellular Interactions of Filamin C. Cardiomyocytes bind to each other at their 
longitudinal extremes by means of intercalated disks (A). Filamin C directly interacts with 
components of the fascia adherens, allowing for the attachment of Z-disk components to the 
intercalated disks. Filamin C is also localized at costameres that couple the sarcomere to the 
lateral sarcolemma and to the extracellular matrix (B). 
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(n = 28; 17 males) 
Relatives with the 
Mutation  
(n = 54; 28 males) 
All Carriers  









SYMPTOMS               
Asymptomatic 28 3 11 51 30 59 79 33 42
Dyspnea 28 12 43 51 5 10 79 17 22
Chest pain 28 4 14 51 3 6 79 7 9
Muscle weakness 28 0 0 48 0 0 76 0 0
Syncope 28 4 14 51 7 14 79 11 14
Palpitations 28 6 21 51 9 18 79 15 19
Sudden death 28 1 4 51 3 6 79 4 5
Minor stroke 28 1 4 51 0 0 79 1 1
ECG               
Sinus rhythm 27 22 81 47 45 96 74 67 91
Atrial fibrillation 27 4 15 47 2 4 74 6 8
Pacemaker (atrial) 27 1 4 47 0 0 74 1 1
Cardiac conduction 
defects* 27 8 30 47 1 2 74 9 12
26 
Low voltages 25 9 36 47 9 19 72 18 25
Negative Tw all 
locations 21 13 62 46 9 20 67 22 33
Left precordial 
negative Tw 21 6 29 46 2 4 67 8 12
Right precordial 
negative Tw 21 0 0 46 0 0 67 0 0
Left + right 
precordial negative 
Tw 21 0 0 46 3 7 67 3 4
Inferior negative Tw 21 2 10 46 2 4 67 4 6
Inferior + left 
precordial negative 
Tw 21 4 19 46 2 4 67 6 9
Inferior + right 
precordial negative 
Tw 21 1 5 46 0 0 67 1 1
Epsilon wave 21 0 0 46 0 0 67 0 0
Terminal QRS >55 
ms 20 5 25 45 7 16 65 12 18
SAECG positive 3 2 67 3 2 67 6 4 67
CARDIAC 
STRUCTURAL               
27 
AFFECTION 
LV dilation 27 19 70 47 15 32 74 34 46
LVEF <55% 27 26 96 49 25 51 76 51 67
MLVWT ≥12 mm 27 5 19 50 5 10 77 10 13
MLVWT ≥15 mm 27 0 0 50 0 0 77 0 0
LV 
hypertrabeculation 27 2 7 47 4 9 74 6 8
RV 
dilat/akin/dyskin/sys
t dysf 28 10 36 48 5 10 76 15 20
Myocardium 
fibrosis 20 15 75 31 16 52 51 31 61
LV fibrosis 19 14 74 30 15 50 49 29 59
RV fibrosis 20 1 5 31 1 3 51 2 4
ARRHYTHMIAS               
FVE (>500/24 h) 23 16 70 32 17 53 55 33 60
NSVT 23 19 83 32 9 28 55 28 51
SVT 23 6 26 32 4 13 55 10 18
Ventricular  
arrhythmia (any) 23 22 96 32 23 72 55 45 82
EPS positive 3 2 67 5 2 40 8 4 50
SKELETAL 
MYOPATHY               
28 
Clinical myopathy 28 1 4 48 0 0 76 1 1
Elevated CK plasma 
levels 21 2 10 19 1 5 40 3 8
OTHER               
Palmoplantar 
keratoderma 27 1 4 49 3 6 76 4 5
EVENTS               
Sudden death 28 5 18 54 7 13 82 12 15
Appropriate ICD 
shock 28 4 14 54 4 7 82 8 10
Heart failure death 28 0 0 54 0 0 82 0 0
Heart transplant 28 5 18 54 0 0 82 5 6
Stroke 28 2 7 54 0 0 82 2 2
 
Values are n unless otherwise indicated. 
*Includes bundle branch block.  
CK = creatine kinase; EPS = electrophysiological study; ECG = electrocardiogram; FVE = frequent ventricular 
extrasystoles; ICD = implantable cardioverter-defibrillator; LV = left ventricular; LVEF = left ventricular ejection 
fraction; MLVWT = maximal left ventricular wall thickness; NSVT = nonsustained ventricular tachycardia; RV = right 
ventricular; RV dilat/akin/dyskin/syst dysf = right ventricular dilation, akinesia, dyskinesia, or systolic dysfunction; 
SAECG = signal-average ECG; SVT = sustained ventricular tachycardia; Terminal QRS >55 ms = S wave upstroke of the 
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Table S1: List of different referring phenotypes related with inherited cardiovascular diseases 
evaluated through next generation sequencing. 
 
Referring phenotype Number of studies 
Hypertrophic cardiomyopathy 1078 
Dilated cardiomyopathy 508 
Arrhythmogenic cardiomyopathy 219 
Ascending aortic disease/Marfan Syndrome
214 
Long QT syndrome 188 
Left ventricular non-compaction-hypertrabeculation 159 
Brugada syndrome 135
Sudden death of unknown cause 131
Idiopathic ventricular fibrillation 52 
Catecholaminergic Polymorphic Ventricular Tachycardia 49 
Restrictive Cardiomyopathy 45 
Noonan Syndrome/Cardiofaciocutaneous Syndrome 30 
Cardiac Conduction Disease 
19 
Ehlers-Danlos Syndrome 16 
Hereditary hemorrhagic telangiectasia/Primary pulmonary hypertension 16 
Short QT syndrome 11 
























Table S2: List of 213 genes related to inherited cardiovascular diseases and sudden death included 
in our custom probe library. 
 
Gene name Codified protein 
AARS2 Alanine--tRNA ligase, mitochondrial 
ABCC9 ATP-binding cassette, sub-family C (CFTR/MRP), member 9 
ACAD9 Acyl-CoA dehydrogenase family member 9, mitochondrial 
ACADM Medium-chain specific acyl-CoA dehydrogenase, mitochondrial 
ACADVL Very long-chain specific acyl-CoA dehydrogenase, mitochondrial 
ACTA1 Actin, alfa 1, skeletal muscle 
ACTA2 Actin, aortic smooth muscle 
ACTC1 Actin, alpha cardiac muscle 1 
ACTN2 Alpha-actinin-2 
ACVRL1 Serine/threonine-protein kinase receptor R3 
ADAMTSL4 ADAMTS-like protein 4 
AGK Acylglycerol kinase, mitochondrial 
AGL Glycogen debranching enzyme 
AGPAT2 1-acyl-sn-glycerol-3-phosphate acyltransferase beta 
AKAP9 A-kinase anchor protein 9 
ALMS1 Alstrom syndrome protein 1 
ANK2 Ankyrin 2 
ANK3 Ankyrin-3 
ANKRD1 Ankyrin repeat domain-containing protein 1 
APOA5 Apolipoprotein A-V 
APOB Apolipoprotein B-100 
APOC3 Apolipoprotein C-III 
ATPAF2 ATP synthase mitochondrial F1 complex assembly factor 2 
BAG3 BAG family molecular chaperone regulator 3 
BMPR1B Bone morphogenetic protein receptor type-1B 
BMPR2 Bone morphogenetic protein receptor type II 
BRAF Serine/threonine-protein kinase B-raf 
BSCL2 Seipin 
CACNA1C Voltage-dependent L-type calcium channel subunit alpha-1C 
CACNA1D Voltage-dependent L-type calcium channel subunit alpha-1D 
CACNA2D1 Voltage-dependent calcium channel subunit alpha-2/delta-1 
CACNB2 Voltage-dependent L-type calcium channel subunit beta-2 
CALM1 Calmodulin 
CALM2 Calmodulin 





CBL E3 ubiquitin-protein ligase CBL 
CBS Cystathionine beta-synthase 
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CETP Cholesteryl ester transfer protein 
COL1A1 Collagen alpha-1(I) chain 
COL1A2 Collagen alpha-2(I) chain 
COL3A1 Collagen alpha-1(III) chain 
COL5A1 Collagen alpha-1(V) chain 
COL5A2 Collagen alpha-2(V) chain 
COQ2 4-hydroxybenzoate polyprenyltransferase, mitochondrial 
COX15 Cytochrome c oxidase assembly protein COX15 homolog 
COX6B1 Cytochrome c oxidase subunit 6B1 
CRELD1 Cysteine-rich with EGF-like domain protein 1 
CRYAB Alpha-crystallin B chain 
CSRP3 Cysteine and glycine-rich protein 3 
CTF1 Cardiotrophin 1 
CTNNA3 Catenin alpha-3 
DES Desmin 
DLD Dihydrolipoyl dehydrogenase, mitochondrial 
DMD Dystrophin 
DNAJC19 Mitochondrial import inner membrane translocase subunit TIM14 
DOLK Dolichol kinase 
DSC2 Desmocollin 2 
DSG2 Desmoglein 2 
DSP Desmoplakin 




EYA4 Eyes absent homolog 4 
FAH Fumarylacetoacetase 
FBN1 Fibrillin 1 
FBN2 Fibrillin 2 
FHL1 Four and a half LIM domains protein 1 
FHL2 Four and a half LIM domains 2 
FHOD3 FH1/FH2 domain-containing protein 3 




FOXD4 Forkhead box protein D4 
GAA Lysosomal alpha-glucosidase 
GATA4 Transcription factor GATA-4 
GATA6 Transcription factor GATA-6 
GATAD1 GATA zinc finger domain-containing protein 1 
GDF2 Growth/differentiation factor 2 
GFM1 Elongation factor G, mitochondrial 
GJA1 Gap junction alpha-1 protein 
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GJA5 Gap junction alpha-5 protein 
GLA Alpha-galactosidase A 
GLB1 Beta-galactosidase 
GNPTAB N-acetylglucosamine-1-phosphotransferase subunits alpha/beta 
GPD1L Glycerol-3-phospate dehydrogenase 1-like protein 
GUSB Beta-glucuronidase 
HCN4 Potassium/sodium hyperpolarization-activated cyclic nucleotide-gated channel 4 
HFE Hereditary hemochromatosis protein 
HRAS GTPase HRas 
JAG1 Jagged-1 
JPH2 Junctophilin 2 
JUP Junction plakoglobin 
KCNA5 Potassium voltage-gated channel subfamily A member 5 
KCND3 Potassium voltage-gated channel subfamily D member 3 
KCNE1 Potassium voltage-gated channel subfamily E member 1 
KCNE1L Potassium voltage-gated channel subfamily E member 1-like protein 
KCNE2 Potassium voltage-gated channel subfamily E member 2 
KCNE3 Potassium voltage-gated channel subfamily E member 3 
KCNH2 Potassium voltage-gated channel subfamily H member 2 
KCNJ2 Inward rectifier potassium channel 2 
KCNJ5 G protein-activated inward rectifier potassium channel 4 
KCNJ8 ATP-sensitive inward rectifier potassium channel 8 
KCNK3 Potassium channel subfamily K member 3 
KCNQ1 Potassium voltage-gated channel subfamily KQT member 1 
KLF10 Krueppel-like factor 10 
KRAS GTPase KRas 
LAMA2 Laminin subunit alpha-2 
LAMA4 Laminin subunit alpha-4 
LAMP2 Lysosome-associated membrane glycoprotein 2 
LDB3 LIM domain-binding protein 3 
LDLR Low density lipoprotein receptor 
LIAS Lipoyl synthase, mitochondrial 
LMNA Prelamin-A/C 
LRP6 Low-density lipoprotein receptor-related protein 6 
MAP2K1 Dual specificity mitogen-activated protein kinase kinase 1 
MAP2K2 Dual specificity mitogen-activated protein kinase kinase 2 
MIB1 E3 ubiquitin-protein ligase MIB1 
MLYCD Malonyl-CoA decarboxylase, mitochondrial 
MRPL3 39S ribosomal protein L3, mitochondrial 
MRPS22 28S ribosomal protein S22, mitochondrial 
MTO1 Protein MTO1 homolog, mitochondrial 
MURC Muscle-related coiled-coil protein 





MYL2 Myosin regulatory light chain 2, ventricular/cardiac muscle isoform 
MYL3 Myosin light chain 3 
MYLK Myosin light chain kinase, smooth muscle 
MYLK2 Myosin light chain kinase 2, skeletal/cardiac muscle 
MYOT Myotilin 




NKX2-5 Homeobox protein Nkx-2.5 
NOTCH1 Neurogenic locus notch homolog protein 1 
NOTCH3 Neurogenic locus notch homolog protein 3 
NPPA Atrial natriuretic factor 
NRAS GTPase NRas 
OBSL1 Obscurin-like protein 1 
PCSK9 Proprotein convertase subtilisin/kexin type 9 
PDHA1 Pyruvate dehydrogenase E1 component subunit alpha, somatic form, mitochondrial 
PDLIM3 PDZ and LIM domain protein 3 
PHKA1 Phosphorylase b kinase regulatory subunit alpha, skeletal muscle isoform 
PITX2 Pituitary homeobox 2 
PKP2 Plakophilin 2 
PLN Cardiac phospholamban 
PLOD1 Procollagen-lysine,2-oxoglutarate 5-dioxygenase 1 
PMM2 Phosphomannomutase 2 
PRDM16 PR domain zinc finger protein 16 
PRKAG2 5'-AMP-activated protein kinase subunit gamma-2 
PRKG1 cGMP-dependent protein kinase 1 
PSEN1 Presenilin-1 
PSEN2 Presenilin 2 
PTPN11 Tyrosine-protein phosphatase non-receptor type 11 
RAF1 RAF proto-oncogene serine/threonine-protein kinase 
RANGRF Ran guanine nucleotide release factor 
RBM20 Probable RNA-binding protein 20 
RYR2 Ryanodine receptor 2 
SCN10A Sodium channel protein type 10 subunit alpha 
SCN1B Sodium channel subunit beta-1 
SCN2B Sodium channel subunit beta-2 
SCN3B Sodium channel subunit beta-3 
SCN4B Sodium channel subunit beta-4 




SHOC2 Leucine-rich repeat protein SHOC-2 
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SKI Ski oncogene 
SLC22A5 Solute carrier family 22 member 5 
SLC25A4 ADP/ATP translocase 1 
SLC2A10 Solute carrier family 2, facilitated glucose transporter member 10 
SLMAP Sarcolemmal membrane-associated protein 
SMAD1 Mothers against decapentaplegic homolog 1 
SMAD3 Mothers against decapentaplegic homolog 3 
SMAD4 Mothers against decapentaplegic homolog 4 
SMAD9 Mothers against decapentaplegic homolog 9 
SNTA1 Alpha-1-syntrophin 
SOS1 Son of sevenless homolog 1 
SPRED1 Sprouty-related, EVH1 domain-containing protein 1 
SURF1 Surfeit locus protein 1 
TAZ Tafazzin 
TBX1 T-box transcription factor TBX1 
TBX20 T-box transcription factor TBX20 
TBX5 T-box transcription factor TBX5 
TCAP Telethonin 
TGFB2 Transforming growth factor beta-2 
TGFB3 Transforming growth factor, beta 3 
TGFBR1 TGF-beta receptor type-1 
TGFBR2 TGF-beta receptor type-2 
TMEM43 Transmembrane protein 43 
TMEM70 Transmembrane protein 70, mitochondrial 
TMPO Thymopoietin 
TNNC1 Troponin C, slow skeletal and cardiac muscles 
TNNI3 Troponin I, cardiac muscle 
TNNT2 Troponin T, cardiac muscle 
TPM1 Tropomyosin alpha-1 chain 
TRDN Triadin 
TRIM63 E3 ubiquitin-protein ligase TRIM63 
TRPM4 Transient receptor potential cation channel subfamily M member 4 
TSFM Elongation factor Ts, mitochondria 
TTN Titin 
TTR Transthyretin 
TXNRD2 Thioredoxin reductase 2, mitochondrial 
VCL Vinculin        
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Chr DNA level name c.DNA Protein Predicted functional effect 1KG EVS ExAC Previously reported 
Ex1 Chr7:128470932delC c.241delC p.Arg81Alafs*15 Introduces a premature stop codon at amino acid 95, 
after 14 novel residues. Truncation in the CH1 domain 
at the ABD. 
- - - - 















p.Gly201Valfs*36 Complete deletion of exons 3, 4, 5, and part of 6. 
Truncation in the CH2 domain. Eliminates the splicing 
acceptor of exon 3. Possible skipping of exon 3 with a 
loss of amino acids 201-233 (CH2 domain at the ABD), 
frame shift at this point, addition of 3 new amino acids, 
and stop codon at position (c.711). Implies the loss of 
the last 2524 amino acids.  
- - - - 
Ex11 Chr7:128480925C>T c.1714C>T p.Gln572* Truncation in the Ig-repeat 4. - - - - 
Ex14 Chr7:128482371delT c.2208delT p.Lys737Serfs*11 Truncation in the Ig-repeat 5. - - - - 






p.Phe1135Alafs*62 Truncation in the Ig-repeat 10. - - - - 
Int21 Chr7:128486043G>A c.3791-1G>A - Eliminates the splicing acceptor of exon 22. Possible 
skipping of exon 22 with a loss of amino acids 1265-
1322  (Ig-repeat 11). 
- - - - 
Int21 Chr7:128486043G>C c.3791-1G>C (2) - Eliminates the splicing acceptor of exon 22. Possible 
skipping of exon 22 with a loss of amino acids 1265-
1322 (Ig-repeat 11). 
- - 1/118498 Two cases with dilated 
cardiomyopathy (1,2) 
Int22 Chr7:128486353A>T c.3965-2A>T (2) - Eliminates the splicing acceptor of exon 23. Possible 
skipping of exon 23 with a loss of amino acids 1322-
1376) (Ig-repeat 11-12), frame shift at this point, 
addition of 8 new amino acids, and stop codon at 
position 1330 (c.4154). Implies the loss of the last 1403 
amino acids. 
- - - - 
Ex23 Chr7:128486496_128486497dupA c.4106_4107dupA p.Asn1369Lysfs*36 Truncation in the Ig-repeat 12. - - - - 
Int23 Chr7:128486518delG c.4127+1delG (2) - Abolishes the splicing donor of exon 23. Two 
alternatives:  
1) A possible loss of amino acid 1376 (Ig-repeat 12), 
frame shift at this point, addition of 6 new amino acids, 
and stop codon at position (c.4127+18). Implies the loss 
of the last 1350 amino acids.   
2) Possible skipping of exon 23 (Ig-repeat 12), frame 
- - - - 
 10
shift at this point, addition of 9 new amino acids, and 
stop codon at position 1386 (c.4154). Implies the loss of 
the last 1401 amino acids. 
Int26 Chr7:128488123G>T c.4580+1G>T - Eliminates the splicing donor of exon 26. Possible 
skipping of exon 26 with a loss of amino acids 1486-
1527 (Ig-repeat 13), frame shift at this point, addition of 
80 new amino acids, and stop codon at position 1566 
(c.4817). Implies the loss of the last 1239 amino acids. 
- - - - 
Int28 Chr7:128489037delG c.4927+1delG - Abolishes the splicing donor of exon 28. Two 
alternatives:  
1) A possible loss of amino acid 1643 (Ig-repeat 15), 
frame shift at this point, addition of 53 new amino 
acids, and stop codon at position (c.4928-38). Implies 
the loss of the last 1083 amino acids.  
2) Possible skipping of exon 28, (Ig-repeat 15), frame 
shift at this point, addition of 22 new amino acids, and 
stop codon at position 1665 (c.4994). Implies the loss of 
the last 1145 amino acids. 
- - - - 
Ex32 Chr7:128490537G>T c.5398G>T (2) p.Gly1800* Truncation in the Ig-repeat 16. - - - - 
Int33 Chr7:128490998G>C c.5539+1G>C - Abolishes the splicing donor of exon 33. Possible 
skipping of exon 33 with a loss of amino acids 1800-
1846 (Ig-repeat 16). 
- - - - 
Ex37 Chr7:128493085G>A c.6208G>A p.Gly2070Ser The splicing is likely to be altered (as predicted by 3 
software tools) but the consequences are not 
predictable. 
- - - - 






p.Pro2081Leufs*2 Truncation in the Ig-repeat 19.    - 
Ex41 Chr7:128494715C>T c.6976C>T (2) p.Arg2326* Truncation in the Ig-repeat 21. - - 1/111082 - 
Int43 Chr7:128495369G>A c.7251+1G>A - Abolishes the splicing donor of exon 43. Possible 
skipping of exon 43 (Ig-repeat 21 and 22), frame shift at 
this point, addition of 23 new amino acids, and stop 
codon at position 2440 (c.7320). Implies the loss of the 
last 346 amino acids. 
- - - Two families with dilated 
cardiomyopathy (3) 
Ex48 Chr7:128498506delG c.8107delG p.Asp2703Thrfs*69 Replacement of 23 amino acids at the C-terminal tail 
(dimerization domain) and extension of 45 amino acids.  
- - - - 
 
ABD= actin binding domain. Ig-repeat= immunoglobulin-like repeat. CH1= calponin homology domain 1. CH2= calponin homology domain 2. (2)= mutations identified in 
two unrelated families. Reference sequence for names at chromosomal DNA level: NC_000007.13; cDNA level: NM_001458.4; protein level: NP_001449.3. 1KG= 1000 
Genomes Project. EVS= Exome Variant Server. ExAC= Exome Aggregation Consortium. Frequency is expressed Nº of alternative alleles/Total Nº of alleles.   
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Table S4: Detailed clinical information on FLNC mutation carriers. 
 



































25767 III:1 Ser2077Argfs*50 48 52 M + D - DCM 83 27 norm
al 






HTx 52     
25767 III:2 Ser2077Argfs*50 59 59 M  P, AF - DCM 67 35 10 - n/a S - - V4-
V6 
+ n/a n/a n/a - n/a n      
25767 IV:1 Ser2077Argfs*50   33 F  n - Healthy 42 65 9 - n/a S - - - - n/a n/a n/a - n/a n      
25767 IV:3 Ser2077Argfs*50   30 F  n - Healthy 44 65 6 - n/a S - - - - n/a n/a n/a - n/a n      
26958 II:1 Tyr83* 17 17 M + SD - LDACM n/a n/a norm
al 
- n/a n/a n/a n/a n/a n/a n/a n/a n/a - LV 
subepicardial 
fibrosis 
SD 17   SD after a 
soccer match. 
26958 I:1 Tyr83* 49 49 M  n - Affected? 53 60 12 + n/a S - - - - - n/a n - n/a n    Mild 
dyskinetic 
zone/saculati
on on anterior 
RV wall on 
cardiac-MRI. 
27103 III:1 c.3791-1G>C 45 52 F + n - DCM 58 35 8 - n/a S - - - - FVE, 
NSVT, 
SVT 


















- n/a S - - - - - n/a n - n/a n    Normal 
SAECG. 
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27348 II:3 Asn1369Lysfs*36 20 60 M + SVT - DCM 82 32 13 + N AF - + V4-
V6 
















27348 III:2 Asn1369Lysfs*36 34 38 F  FVE - Affected? 45 64 10 - n/a S - - - - FVE n/a n/a - n/a n      
29544 III:2 Pro963Argfs*26 0.2
5 
1 F - D - DCM 40 22 norm
al 






HTx 1     
29544 II:1 Pro963Argfs*26 40 40 F  n - Affected? dilat
ed








29876 III:3 c.4127+1delG 19 25 M + S, P - LDACM 61 54 11 - N S - - - - FVE, SVT n/a LV 
(subepicar
dial) 
+ LV fibrosis aICDs; 
SD 








29876 II:5 c.4127+1delG 43 57 M  S, P - DCM 60 50 12 - N S - - - - SVT SV
T  







due to SVT. 
Palmoplantar 
keratosis. 
29876 II:3 c.4127+1delG 60 60 F  n - LDACM 51 67 12 - n/a S - - - - FVE n/a LV 
(intramyoc
ardial) 
- n/a n      
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29876 II:4 c.4127+1delG 35 59 M  D, S - DCM 64 43 11 - n/a AF LAFB - - - FVE, 
NSVT 
n/a n - n/a n    Palmoplantar 
keratosis. 











- n/a n    Palmoplantar 
keratosis. 
29876 III:5 c.4127+1delG 21 21 M  n - LDACM 51 52 10 - n/a S - - - - - n/a LV 
(intramyoc
ardial) 
- n/a n      
31035 IV:1 c.7251+1G>A 26 33 F + NSVT - DCM 66 23 6 - N S - + V3-
V6 
+ NSVT - n/a - n/a n  1º  
31035 III:2 c.7251+1G>A 38 61 F  n - DCM 64 33 10 - n/a S - + V1-
V5 
+ n/a n/a n/a - n/a n  1º   
31035 IV:4 c.7251+1G>A   39 F  n - Healthy 52 68 6 - n/a S - - - - - n/a n - n/a n     
31035 III:5 c.7251+1G>A 58 63 F  n - DCM 66 35 8 - n/a S - - V1-
V6 
+ FVE n/a n/a - n/a n  1º   
31035 IV:6 c.7251+1G>A 39 39 F  n - Affected? 46 54 8 - n/a S - - - - - n/a n/a - n/a n     
31035 IV:7 c.7251+1G>A 40 40 F  SD n/a LDACM n/a n/a norm
al 




SD 40    
31277 II:2 c.4927+1 delG 29 55 F - D + RCM 32 66 14 - Mil
d 
AF 1ºAVB - V5-
V6 
- n/a n/a n/a - RV fibrosis 
(endomyocar
dial biopsy) 
HTx 45     
32406 III:2 Gln572* 20 22 M + P - LDACM 68 37 norm
al 
+ n/a S - + V5-
V6 















33319 II:1 c.4127+1delG 53 63 M - D - DCM dilat
ed
15 n/a + N AF - n/a n/a n/a n/a n/a LV 
(transmura
l) 
n/a n/a n      






S - - - - n/a n/a LV 
(intramyoc
ardial) 
n/a n/a n      
33319 III:1 c.4127+1delG   32 F  n n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n      
33541 II:3 c.5539+1G>C 60 68 M + D, CP, 
FVE 










- n/a n  1º   
33541 II:5 c.5539+1G>C 55 63 M  SD - DCM dilat
ed





- n/a SD; 
aICDs






33541 II:6 c.5539+1G>C 59 60 F  S, D, P - Affected? 50 55 9 - N S - - - - FVE n/a LV 
(intramyoc
ardial) 
- n/a n      
33541 III:1 c.5539+1G>C   39 F  n - Healthy 38 60 8 - N S - - - - - n/a n - n/a n      











33675 II:2 Gly1800* 60 63 M  n - Affected? 37 67 14 - N S - - - - n/a n/a n + n/a n    HTN. 









- n/a HTx 57   Emergent 
HTx. 




- n/a S - + V1-
V4 
- NSVT n/a LV basal 
septum 
- n/a SD 58   Listed for 
HTx prior to 
SD. 
36107 II:6 Arg2326* 57 59 F  S, P - Affected? 54 56 8 - N S - + Inf, 
V1-
V6 
+ FVE - n - n/a n      
36107 III:7 Arg2326*   33 M  n - Healthy 54 60 8 - N S - - - - n/a n/a n - n/a n      
36107 III:2 Arg2326* 33 34 M  S, P - DCM 60 46 11 + N S - - - + FVE n/a LV 
(subepicar
dial) 
- n/a aICDs 33 1º Multiple SVT 
treated by the 
ICD. 









36203 III:1 Gly1800* 38 43 M + P - LDACM dilat
ed









- n/a n  1º Abnormal Q 
wave DIII 
and aVF. 
36203 III:3 Gly1800* 28 38 M  P - LDACM 54 51 11 - n/a n/a n/a n/a n/a n/a n/a n/a n/a - LV fibrosis 
posterior wall
SD 38     





- n/a n  1º Abnormal Q 
wave in DIII. 




- n/a n/a n/a - n/a n      
37286 IV:2 Asp2703Thrfs*69 24 24 F + Stroke - DCM 63 26 7 - N S - + Inf, 
V1-
V3 
- NSVT n/a n + n/a Stroke 24    
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37286 III:1 Asp2703Thrfs*69 43 59 M  S - DCM 70 40 7 n/a N AF - - Inf - SVT - n/a n/a n/a aICDs 51 1º 2 ICD shocks 
on VF. 
















due to SVT 
(38, 39, 40 
yo) and 1 due 
to VF (38 
yo). 
37302 I:1 Gly2070Ser 50 68 M + D - DCM 78 21 norm
al 











n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n    Perimyocardy
tis . 





n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n    Perimyocardy
tis. 
41721 II:2 c.3791-1G>A 42 61 F + P - DCM 56 43 9 - N S LAFB+ 
RBBB 
- - - - n/a n - n/a n     
41721 II:4 c.3791-1G>A 44 52 M  n - DCM 65 45 10 - N S - - - - NSVT - n - n/a n    NSVT during 
effort test. 
41721 II:7 c.3791-1G>A (o)     F  n/a n/a DCM n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a SD ?     
41721 III:1 c.3791-1G>A 20 34 M  n - DCM 64 49 10 - N S - - - - FVE, 
NSVT 








n/a n - n/a SD 33     
47263 III:2 Phe1135Alafs*62 53 55 F + n - DCM 56 20 12 - N S - - - - FVE, 
NSVT 
n/a n/a - n/a n  1º CRT-D 
47253 IV:3 Phe1135Alafs*62   24 M  n - Healthy 54 68 8 - n/a S - - - - n/a n/a n/a - n/a n      
47263 IV:1 Phe1135Alafs*62   30 F  n - Healthy 50 73 9 - n/a S - - - - n/a n/a n/a - n/a n     
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47263 IV:2 Phe1135Alafs*62 28 29 M  n - Affected? 60 53 11 - n/a S - - - + n/a n/a n - n/a n    Abnormal Q 
wave DIII. 
48028 III:1 Lys737Serfs*11 58 62 F + D, FVE, 
NSVT 





- n/a n     
48028 III:2 Lys737Serfs*11 44 60 F  D, P - DCM 57 40 8 + n/a S - - - + FVE, 
NSVT 
n/a n/a - RV fibrosis 
(endomyocar
dial biopsy) 
n      
48028 IV:1 Lys737Serfs*11   31 F  n - Healthy 46 60 7 - n/a S - - - - n/a n/a n/a - n/a n      
48102 II:1 c.3791-1G>C 44 50 M + S - DCM? 52 50 11 - n/a S - + Inf - NSVT n/a n/a - n/a SD 44 2º NSVT on 





SD.   




+ n/a S - + - - FVE NS
VT 




















n/a n - n/a n  1º   





SD 60    
48924 III:1 p.Leu194Profs*52 51 51 F  n - Affected? 51 49 10 - N S - - - - - n/a n - n/a n      
48924 IV:1 p.Leu194Profs*52   18 M  n - Healthy 49 60 10 - n/a S - - - - - n/a n - n/a n    Myocarditis 
aged 13. 
49537 I:1 c.3965-2A>T 55 66 M - D, CP, 
SVT 
- DCM 81 15 8 + N S LBBB - n/a n/a FVE, 
NSVT, 
SVT 
n/a n/a - n/a aICDs 62 2º  
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49537 II:1 c.3965-2A>T 36 41 M  P, SVT - DCM 52 42 11 - n/a S - - - - SVT n/a n/a - n/a n  2º  
49537 III:3 c.3965-2A>T 34 38 M  P - DCM 61 45 10 - N S - - - - FVE n/a LV 
(intramyoc
ardial) 
+ n/a n  1º   







- n/a n  1º   









48956   c.4580+1G>T 53 75 M - S, CP, 
SVT 








- n/a n  2º   
48868   Gly201Valfs*36 47 48 M + D, CP, 
NSVT 
- DCM 71 36 11 + N S LBBB n/a n/a n/a FVE, 
NSVT 
n/a n - n/a Stroke 47   ECG not 
informative 
due to LBBB. 
49818   c.3965-2A>T 62 64 M + D - DCM 54 18 13 + N S - + Inf + FVE, 
NSVT, 
SVT 












- n/a n  1º   












- n/a n      
51118  I:2 Arg81Alafs*15   72 F  n - Healthy 48 60 10 - N S - - - - n/a n/a n/a - n/a n      
 
Grey shaded files indicate probands. Fam= familiy number. Ind= individual identification according to position in the pedigree. (o)= obligate carrier of the mutation. Age Dx= 
age at diagnosis. Age LFU= age at last follow-up. M= male; F= female. FHSD= family history of sudden death. Clinical press= signs or symptoms at clinical presentation (D= 
dyspnea; S= syncope; P= palpitations; AF= atrial fibrillation; NSVT= non-sustained ventricular tachycardia SVT= sustained ventricular tachycardia; FVE= frequent 
ventricular ectopics; SD= sudden death; CP= chest pain). SM= presence of clinical signs of skeletal myopathy. Pheno= phenotype (DCM= dilated cardiomyopathy; LDAC= 
left-dominant arrhythmogenic cardiomyopathy; RCM= restrictive cardiomyopathy; affected?= individual possibly affected but not fulfilling diagnosis of a specific 
cardiomyopathy). LVDD= left ventricular diastole diameter. LVEF= left ventricular ejection fraction (mild= mild depression). MLVWT= maximal left ventricular wall 
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thickness. RV affect= right ventricular affection (akinesia, dyskinesia, aneurysm, dilatation, systolic dysfunction). CK= plasma levels of creatine-kinase (N= normal value; 
mild= mild elevation). Rhythm= cardiac rhythm (S= sinus rhythm; AF= atrial fibrillation; PM= pace-maker). CCD= cardiac conduction defects (1ºAVB= first-degree AV 
block; LBBB= left bundle branch block; RBBB= right bundle branch block; LAFB= left anterior fascicular block). Low volt= low QRS voltage amplitude on limb leads. Neg 
Tw= ECG leads with abnormal negative T waves (inf= DII, DIII, aVF). Vent arrhyt= evidence of ventricular arrhythmias (SVT= sustained ventricular tachycardia; NSVT= 
non-sustained ventricular tachycardia; FVE= frequent ventricular ectopics). EPS= result of electrical endocavitary stimulation. LGE on MRI= presence and localization of late 
gadolinium enhancement on cardiac magnetic resonance images. LVNC= signs of myocardial non-compaction of the left ventricular wall (not necessarily fulfilling diagnosis 
of left ventricular non-compaction cardiomyopathy). Pathology= findings in the pathological evaluation of cardiac necropsy/explanted heart/endomyocardial biopsy. Events= 
cardiovascular events (SD= sudden death; HTx= heart transplant; aICDs= appropriate ICD shock. ICD= implantable cardiac defibrillator indication (1º= primary prevention; 
2º= secondary prevention; ind= indicated but not implanted. + = positive finding. - = negative finding. n/a= not available data. LV= left ventricle. RV= right ventricle. VF= 
ventricular fibrillation. SAECG= signal average ECG. CRT-D= cardiac resynchronization therapy pacemaker with defibrillation therapy. CABG= coronary artery by-pass 
graft.  
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Table S5: Logarithm (base ten) of odds (LOD) scores showing cosegregation of truncating 
mutations in FLNC with the cardiac phenotype in individual families and combined.  
 

































LOD score for each family calculated by means of Superlink-Online SNP tool with the following 
settings: disease mutant gene frequency= 0.001, dominant mode of inheritance, penetrance= 99%, θ=0. 
Individuals ≤40 years without clear clinical affection were consider “unknown phenotype”. n/a= not 










Supplementary Appendix figure legends 
 
Figure S1: Circles, females. Squares, males. Arrows indicate the proband. Clinical status defined by 
cardiac evaluations or clinical records: black, affected; N, unaffected; vertical bar, possibly affected; slash, 
deceased; ?, unknown. Genotypes are indicated: +, FLNC mutation present; 0, obligate carrier; -, FLNC 
mutation absent. Ages below some individuals indicate the age of sudden death (SD), diagnosis of the 
phenotype (DCM, dilated cardiomyopathy), or last clinical follow-up in healthy carriers. yo= years old. 
HTx= heart transplant. PP= palmo-plantar keratoderma. SVT= sustained ventricular tachycardia. HFD= 
heart failure death. PM= pacemaker. 
 
Figure S2: ECG from carrier III:2 of family 31035 (Panel A). ECG from carrier II:1 of family 37296 
(proband) (Panel B). ECG from carrier III:1 (proband) of family 36203 (Panel C). ECG from carrier II:6 
of family 36107 (Panel D). 
 
Figure S4: Proband III:3 of family 29876. Presented with syncope due to sustained ventricular 
tachycardia while playing soccer. A cardiac defibrillator was implanted as secondary prevention. Died 
during a ventricular arrhythmic storm a few days later. Picture shows 10/12 failed appropriate 
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Figure S4: Appropriate defibrillator shock in a patient with a FLNC truncating mutation.  
 
 
 
 
 
 
 
 
